USF-LVHN SELECT
Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium
Publication/Presentation Date
11-2025
Volume
146
Issue
3
First Page
4066
Last Page
4066
Published In/Presented At
Disciplines
Medical Education | Medicine and Health Sciences
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article
COinS